Literature DB >> 17205055

Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

K Summers, J Stevens, I Kakkas, M Smith, L L Smith, F Macdougall, J Cavenagh, D Bonnet, B D Young, T A Lister, J Fitzgibbon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17205055     DOI： 10.1038/sj.leu.2404514

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  23 in total

1.  Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.

Authors:  Subarna Sinha; Daniel Thomas; Linda Yu; Andrew J Gentles; Namyoung Jung; M Ryan Corces-Zimmerman; Steven M Chan; Andreas Reinisch; Andrew P Feinberg; David L Dill; Ravindra Majeti
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

3.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

Review 4.  FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

5.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Peter Paschka; Kelsi B Holland; Sebastian Schwind; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

Review 6.  Epigenetic regulators and their impact on therapy in acute myeloid leukemia.

Authors:  Friederike Pastore; Ross L Levine
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

7.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

8.  Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Klaus H Metzeler; Susan P Whitman; Sebastian Schwind; Jessica Kohlschmidt; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Guido Marcucci; Clara D Bloomfield
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

Review 9.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

10.  Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.

Authors:  Antonia Busse; Anne Letsch; Carmen Scheibenbogen; Anika Nonnenmacher; Sebastian Ochsenreither; Eckhard Thiel; Ulrich Keilholz
Journal:  J Transl Med       Date:  2010-01-21       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.